Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 11/20 | 0.57 |
| ▸ | MET | P08581 | 6/20 | 0.46 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13378058 | 0.76 | RPS6KA5 (0.59) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL3222371 | 0.74 | RPS6KA5 (0.57) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL29509090 | 0.74 | RPS6KA5 (0.57) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL256322 | 0.74 | RPS6KA5 (0.57) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL27987760 | 0.74 | RPS6KA5 (0.57) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL1472997 | 0.74 | RPS6KA5 (0.57) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL1446137 | 0.74 | RPS6KA5 (0.57) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL12011230 | 0.74 | RPS6KA5 (0.57) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL15226076 | 0.69 | RPS6KA5 (0.52) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL15718818 | 0.69 | RPS6KA5 (0.52) | RPS6KA5METRPS6KA4CDC7CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119635-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100016277-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2010-01-21 | — | — | US | disclosed |
| US-7598236-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2008-04-24 | — | — | US | disclosed |
| US-7319106-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2008-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | RPS6KA5 2270/4885MET 4880/4885RPS6KA4 2175/4885 |
| US-20100016277-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | RPS6KA5 2270/4885MET 4880/4885RPS6KA4 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.